We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Regeneron CEO Hopes for FDA Authorization of its COVID-19 Antibody Cocktail ‘Soon’
Regeneron CEO Hopes for FDA Authorization of its COVID-19 Antibody Cocktail ‘Soon’
In an investor call yesterday, Regeneron CEO Leonard Schleifer said he hoped for an early decision by the FDA on an Emergency Use Authorization (EUA) of the company’s COVID-19 antibody cocktail treatment REGN-COV2.